Roivant Shares Jump After Q4 Beat Fueled by Moderna Settlement and Pipeline Milestones
Roivant Sciences rallied sharply in mid-day trading after reporting fiscal Q4 2026 results ahead of the market open. The company posted diluted EPS of $0.28, far exceeding an expected loss of $0.29, driven largely by a $770.2 million gain tied to a litigation settlement with Moderna. Net income swung to $302.99 million from a year-ago loss of $206.…